Open an account

Telesis Bio

TBIO · OTC

$0.0386−$0.0036 (−8.53%)TodayMarket closed ·
No price history for this range.

About TBIO

Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2021-06-18. The firm provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.

Employees
137
Headquarters
San Diego, California
Listed
Jun 18, 2021
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
telesisbio.com

TBIO key statistics

Market cap
3.03M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
347
Volume
1
Open price
$0.0386
High today
$0.0386
Low today
$0.0386
52 Week high
$0.15
52 Week low
$0.0001

Telesis Bio (TBIO) at a glance

As of Oct 16, 2026, Telesis Bio (TBIO) shares are priced at $0.0386, giving the company a market cap of 3.03M and a price-to-earnings ratio of 0.00.

Volume so far is 1 shares, below the average of 347 shares a day.

Over the past year Telesis Bio has ranged from $0.0001 to $0.15, and now sits 26% of the way up that range.

Telesis Bio met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY24 it reported -$3.83 per share against an estimate of -$6.71.

TBIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 23.4% on average.

  1. Q4 FY22: reported -$5.04 per share against an estimate of -$7.59
  2. Q1 FY23: reported -$6.66 per share against an estimate of -$6.85
  3. Q2 FY23: reported -$5.04 per share against an estimate of -$5.88
  4. Q3 FY23: reported -$6.66 per share against an estimate of -$5.45
  5. Q4 FY23: reported -$4.14 per share against an estimate of -$4.04
  6. Q1 FY24: reported -$5.52 per share against an estimate of -$4.22
  7. Q2 FY24: reported -$7.62 per share against an estimate of -$4.11
  8. Q3 FY24: reported -$3.83 per share against an estimate of -$6.71

TBIO news

  • Press releaseBusiness Wire

    Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

  • Press releaseBusiness Wire

    Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

  • Avi Kapoor

    Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

  • Avi Kapoor

    Dow Surges Over 250 Points; Accenture Earnings Top Views

  • Dylan Berman

    What's Going On With Telesis Bio Shares Thursday?

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Crude Oil Down Over 2%; US Initial Jobless Claims Fall

  • Market-Moving News for September 26th

Similar companies

Companies in the same industry as Telesis Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.